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Abstract.
Background: The activity of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer (BC) is promising for many
patients. However, a subset of patients do not benefit from treatment, thus leading to an effort to better identify predictive
molecular biomarkers of response.
Objective: To conduct a systematic review of the literature on predictive molecular biomarkers associated with response
to PD-1 and PD-L1 inhibitors in advanced bladder cancer, defined as locally-advanced, unresectable, or metastatic (mBC)
disease.
Methods: A search of the literature was performed using Embase (1947 – January 2019), Medline (1946 – January 2019), and
EBM Reviews for Cochrane Central Register of Controlled Trials (as of December 2018). Studies examining the association
of molecular biomarkers with clinical outcome in BC treated with PD-1 or PD-L1 monotherapy were included. Outcomes
of interest were overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), duration of response,
and objective response rate (ORR).
Results: Using the study search criteria, 899 unique abstract citations were found, of which 834 did not meet the eligibility
criteria. Full text of the remaining 65 citations were screened, and 50 studies excluded, including 18 review articles. Eight
additional studies from the bibliography of the review papers were included, making a total of 23 studies. Five PD-1 / PD-L1
antibodies have been tested in BC immunohistochemistry (IHC). These studies used different expression scoring criteria
and generally had poor ability to discriminate likelihood for response. Overall, the data suggests CD8+ T cell infiltration is
necessary to mediate an antitumor immune response, but other immune cell populations, such as neutrophils may suppress T
cell-mediated immunity and efficacy of PD-1/PD-L1 blockade. An IFN signature is a promising predictor, but there needs
to be consensus on the optimal gene panel composition, and prospective validation. Tumor mutation burden (TMB) is a
promising predictor in six studies reporting on 1200 patients, but there is not a consensus on the optimal definition of “high
TMB”. Detection of T cell receptor (TCR) clonal expansion has only been conducted in small studies and so its predictive
value remains inconclusive. Epithelial-mesenchymal transformation (EMT) and transforming growth factor  (TGF) are
associated with poor prognosis and possibly intrinsic resistance to PD-1/PD-L1 checkpoint blockade, but more work needs
to be done to build upon and confirm the initial findings.
∗Correspondence to: Dan Theodorescu, Cedars-Sinai Health
System, 8700 Beverly Blvd., OCC Mezz C2002, Los Angeles, CA
90048, USA. Tel.: +1 310 423 8431; E-mail: dan.theodorescu@
cshs.org.
ISSN 2352-3727/19/$35.00 © 2019 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
132 M.M. Tu et al. / Molecular Biomarkers of Response
Conclusions: Currently no molecular biomarker is sufficiently mature for routine clinical use, while some candidates, or a
combination show great promise and need further study.
Keywords: Bladder cancer, biomarkers, immunotherapy, PD-1, PD-L1, atezolizumab, avelumab, durvalumab, nivolumab,
pembrolizumab
INTRODUCTION
Long-term survival in patients with locally-
advanced, unresectable, or metastatic urothelial
bladder cancer (mBC) treated with cisplatin-based
chemotherapy is poor, with a historical 5-year overall
survival rate of 10–15% [1]. In addition, 50% of mBC
patients are unfit for cisplatin due to renal function
impairment, cardiovascular comorbidities and perfor-
mance status [2]. The approval of immune checkpoint
inhibitors (ICI) in multiple cancer types has reinvig-
orated excitement for leveraging the immune system
to treat cancer. CTLA-4 and PD-1 inhibitors have
revolutionized cancer treatment, where previously,
chemotherapy was most often the only available treat-
ment for metastatic disease. Exploration of these
checkpoint inhibitors has led to their approval in
multiple solid tumor types with varying degrees of
clinical benefit. In the past two years alone, five ICI
treatments have been approved by the FDA in multi-
ple treatment settings [3–7].
Here, we present a systematic review highlighting
the current knowledge on molecular biomarkers of
response to PD-1 and PD-L1 blockade in the context
of advanced bladder cancer.
METHODS
Literature search
Electronic search strategies were developed and
tested by a medical information specialist (Risa Shorr,
The Ottawa Hospital, Ottawa, Ontario, Canada) in
consultation with the review team. We searched
Ovid MEDLINE (from 1946 to January 2019)
and Embase Classic+Embase (from 1947 to Jan-
uary 2019). We also searched EBM Reviews –
Cochrane Central Register of Controlled Trials up
to December 2018. The Cochrane Controlled Reg-
ister of Trials was first published in 1996, but its
composite nature means that it does not have an
inception or start date like that of other traditional
biomedical databases [8]. Strategies utilized a com-
bination of controlled vocabulary (e.g., “Urinary
Bladder Neoplasm”) and keywords (bladder cancer
or urothelial carcinoma, checkpoint inhibitor). The
complete search strategy is outlined in Appendix
1. Vocabulary and syntax were adjusted across
databases. Non-human and non-English studies were
excluded. The search did not restrict to specific
study designs. We also searched for additional refer-
ences by hand-searching the bibliographies of review
papers that met our eligibility criteria. Please refer
to Fig. 1 for the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) [9]
flowchart. PRISMA is an evidence-based minimum
set of items for reporting in systematic reviews and
meta-analyses.
Study selection criteria and data collection
Selection criteria for randomized studies
were characterized according to the Population-
Intervention-Comparators-Outcomes-Study design
(PICOS) framework [10]. Non-randomized studies
utilized a similar framework. The study population
of interest were patients diagnosed with advanced
BC, defined by the authors as locally advanced (on
the TNM staging system, T4b and any N; or any T
and N2–3), unresectable (unable, unfit or unwilling
to undergo a cystectomy) or metastatic (M1, stage
IV: spread to a distant site outside of the bladder;
non-regional lymph nodes or visceral metastases)
urothelial bladder cancer, who received anti-PD-1
or anti-PD-L1 monotherapy. Studies that included
mBC only, as well as studies that included them as
a subgroup of the study population were eligible.
We only included studies that investigated the
predictive value of molecular biomarkers, defined as
a measurable marker in blood or tissue that has the
potential to predict response and clinical outcome.
Outcomes of interest included overall survival (OS),
progression-free survival (PFS), time-to-progression
(TTP), duration of response (DoR), objective
response rate (ORR), as well as derivatives of these
clinical endpoints.
In an initial screen, MMT and TLN independently
evaluated all abstracts identified by the literature
search. A second assessment of full-text articles
was performed by MMT, TLN, TCMZ, FCdJ, and
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Fig. 1. PRISMA flowchart outlining the selection criteria for the systematic review.
FGTF. Reasons for study exclusion were recorded
and reported in Fig. 1. The summary of the liter-
ature selection process according to the PRISMA
guidelines is reported in Fig. 1. We collected data
from included studies about study design (random-
ized clinical trial, prospective or retrospective cohort
study, case series), sample size, name of anti-PD-1 or
anti-PD-L1 antibody, type of molecular biomarker
examined, method of marker measurement, and
clinical endpoints reported. Collection of study char-
acteristics and outcomes was performed by MMT and
TLN using a structured form. MMT, TLN, TCMZ,
FCdJ, and FGTF performed primary data collection.
MMT verified all items extracted by other reviewers.
Primary data extracted by MMT was independently
verified by TLN.
RESULTS
PD-L1 expression
Atezolizumab
The earliest study to demonstrate efficacy of PD-
L1 blockade in mBC was the phase 1 expansion
study examining the efficacy of atezolizumab in a
cohort of 205 cisplatin-pretreated mBC patients [3].
The cohort with PD-L1 positive tumor-infiltrating
immune cells (IC) had particularly high response
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Table 1
Complementary diagnostic assays for PD-L1 expression used as a molecular biomarker in clinical trials
PD-L1 Manufacturer ICI used in Scoring method Scoring cutoffs Ref.
Antibody the study
22C3 Dako Pembrolizumab PD-L1-expressing TC and
IC, relative to total TC
Positive:≥10%
Negative:<10%
[16, 18]
PD-L1 detected on TC or in
tumor stroma
Positive:≥1% Negative:<1% [5]
28–8 Dako Nivolumab PD-L1 on TC Positive:≥1% Negative:<1% [4, 36, 47]
Positive:≥5% Negative:<5% [4, 36]
SP263 Roche Durvalumab PD-L1 on TC or IC High:≥25% Low:<25% [6, 41, 66]
PD-L1 on TC and/or IC High:≥25% of either TC or
IC Low or negative:<25%
of both TC and IC
[27]
SP142 Roche Durvalumab PD-L1 on TC Positive:≥1% Negative:<1% [29]
Atezolizumab PD-L1 on IC IC0:<1% IC1:≥1% to < 5%)
IC2/3:≥5%
[3, 11, 12, 14, 45]
73–10 Merck KGaA Avelumab PD-L1 on TC Positive:≥1% (any
intensity),≥5% (any
intensity), or ≥ 25%
(≥2 + staining intensity)
[7]
PD-L1 on IC Positive:≥10%
Abbreviations: ICI, immune checkpoint inhibitor; TC, tumor cell; IC, immune cell.
rates, with many patients having a durable response
[3]. Moreover, elderly mBC patients often present
with impaired renal function, which is a major lim-
iting issue for chemotherapeutic treatment options
in mBC. Atezolizumab’s more favorable toxicity
profile, including less renal toxicity, led to further
development of atezolizumab in both the cisplatin-
pretreated and cisplatin-ineligible population [11,
12]. In a single-arm phase 2 study of 310 mBC
patients who progressed after previous platinum-
based chemotherapy, assuming a historical control
ORR of 10%, atezolizumab demonstrated a sig-
nificantly improved RECISTv1.1[13] ORR in the
overall study population (15% [95% CI: 11–20],
p = 0.0058), in the PD-L1 immune cell (IC) 1/2/3
group (PD-L1 expression ≥ 1%) (18% [95% CI:
13–24], p = 0.0004), and in the IC 2/3 group (PD-L1
expression ≥ 5%) (27% [95% CI: 19–37],p < 0.0001)
(Table 1, complementary diagnostic PD-L1 assay
SP142) [11]. The single-arm phase 2 study also
showed that tumor mutational burden (TMB) and
TCGA luminal cluster 2 were associated with an
increased response rate [11].
Table 1 highlights the different antibodies currently
used in the clinic to measure PD-L1 expression. It
should be noted that the antibodies currently used
vary based on the immune checkpoint inhibitor of
the study, as well as having different thresholds for
expression level classification.
In another single-arm phase 2 study of 119
untreated cisplatin-ineligible mBC patients, ate-
zolizumab demonstrated an improvement in ORR
[12]. However, there was no difference in ORR, PFS,
or OS based on stratification of PD-L1 expression
on ICs. In May 2016, the FDA granted accelerated
approval to atezolizumab based on promising efficacy
data in single arm phase 2 studies for both cisplatin-
pretreated and cisplatin-ineligible mBC patients [11,
12].
Although these two studies led to the accelerated
approval of atezolizumab, a phase 3 random-
ized control trial of 931 platinum-pretreated mBC
patients randomized to atezolizumab or second-line
chemotherapy (vinflunine, paclitaxel, or docetaxel)
did not demonstrate improved overall survival in the
IC 2/3 subgroup, which was their pre-planned pri-
mary endpoint based on previous studies [14]. There
was no difference in the ORR. However, there was
a numerical difference in duration of response (15.0
months versus 8.3 months) favoring atezolizumab.
Further analyses from this study confirmed the lack of
difference in OS regardless of PD-L1 subgroup (both
IC 2/3 and IC 1/2/3). Although there was a signifi-
cant improvement in OS favoring atezolizumab over
chemotherapy in the intention-to-treat (ITT) popu-
lation (n = 931), HR = 0.85 (95% CI: 0.73 to 0.99),
a median OS (mOS) difference of 0.6 months (8.6
months vs. 8.0 months) was not clinically meaning-
ful. However, further assessment of the high TMB
subgroup (n = 274) did show a meaningful difference
in mOS (11.3 versus 8.3 months, HR 0.68 [95% CI:
0.51 to 0.80]) favoring atezolizumab [15].
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Table 2
Clinical benefit of biomarkers to PD-1/PD-L1 therapy
Biomarker Biomarker Predictive Total sample size Reference
Value (n =)
PD-L1
Atezolizumab: 515 [3, 11]
+ Durvalumab: 191 [6, 27]
Avelumab: 293 [7, 28]
Atezolizumab: 586 [12, 14]
– Pembrolizumab: 384 [16, 18, 29]
Nivolumab: 351 [4, 36]
TCR clonal expansion + 44 [29, 46]
CD8+ T cell infiltration + 124 [29, 30]
Tumor mutation burden
+ 1107 [11, 12, 14, 29, 45, 47]
– 29 [46]
IFN + 301 [36, 40, 41]
Abbreviations: TCR, T cell receptor; IFN, interferon; +, predictive of clinical benefit; –, not predic-
tive of clinical benefit.
Overall, atezolizumab showed promising early
results [3, 11, 12], which was unfortunately not val-
idated in the phase 3 trial [14]. Based on the current
data, PD-L1 expression using the SP142 assay cannot
be used to predict clinical benefit from atezolizumab
(Table 2).
Pembrolizumab
The KEYNOTE-012 study (n = 33) first estab-
lished safety and efficacy of pembrolizumab in mBC
[5]. PD-L1 expression was examined on both tumor
and stroma and found ORR to be higher in the PD-
L1-negative tumor cell (TC) subgroup compared to
the PD-L1-positive TC subgroup (27% vs. 14%)
(Table 1, complementary diagnostic assay PD-L1
clone 22C3). In contrast, patients with detectable
PD-L1 expression on both TC and stroma had
higher ORR than those that were PD-L1 negative
in both TC and stroma (ORR 24% versus 0%)
[5]. Two studies reported on the efficacy of pem-
brolizumab in patients that recurred or progressed
after platinum-based chemotherapy, and in patients
that were ineligible for platinum-based treatment,
respectively. In KEYNOTE-045, a phase 3 ran-
domized study of 542 platinum-pretreated mBC
patients, 270 patients randomized to pembrolizumab
had a significantly improved OS compared to sin-
gle agent chemotherapy [16]. A two-year follow-up
showed an OS benefit with pembrolizumab in all
PD-L1 subgroups (HR: Combined Positive Score
[CPS] < 1%, 0.82; CPS ≥ 1%, 0.58; CPS < 10%,
0.75; CPS ≥ 10%, 0.56) (Table 1, Complementary
diagnostic PD-L1 assay Dako 22C3) [17]. For first-
line, cisplatin-ineligible patients, KEYNOTE-052, a
single-arm phase 2 trial of 370 mBC patients had
an ORR of 24% in the overall cohort and an ORR of
38% in the subgroup with a PD-L1 expression ≥ 10%
[18]. Longer follow-up on this study confirmed an
ORR of 29% in the ITT group and ORR 47% in
the PD-L1 CPS ≥ 10% group. Sensitivity and speci-
ficity testing of the first 100 patients who had tissue
for analysis showed that, PD-L1 CPS had a ROC
AUC 0.58, p = 0.111 (n = 96). The variability of the
available study data suggests that PD-L1 immuno-
histochemistry (IHC) does not have the ability to
discern responders from non-responders. The results
of KEYNOTE-045 and KEYNOTE-052 support the
use of pembrolizumab in mBC in different clinical
scenarios.
From the IMvigor130 (atezolizumab) and
KEYNOTE-361 (pembrolizumab) studies, both
randomized studies that contained a chemotherapy
monotherapy arm and a PD-1 (pembrolizumab)
or PD-L1 (atezolizumab) inhibitor monotherapy
arm, the Data Monitoring Committee (DMC) noted
that in subgroups with low PD-L1 expression,
patients receiving pembrolizumab or atezolizumab
monotherapy had worse overall survival compared
to patients receiving platinum-based chemotherapy
based on the preliminary analysis [19–21]. As such,
both the KEYNOTE-361 and the IMvigor130 trials
have stopped enrolling patients with PD-L1–low
status to the monotherapy arms, and the FDA
now requires PD-L1 testing for patients receiving
first-line pembrolizumab or atezolizumab unless
they are not eligible to receive any platinum-based
chemotherapy [19]. These results highlight the need
for ICI use to be anchored by careful selection of
136 M.M. Tu et al. / Molecular Biomarkers of Response
patients that will most likely benefit from treat-
ment. This is compounded by the financial costs
and clinical toxicity associated with these agents
[22–25].
Nivolumab
A multi-arm phase 1/2 study (CheckMate-032) of
86 mBC patients with recurrent metastatic urothelial
carcinoma reported an investigator-assessed ORR of
24.4% (95% CI: 15.3–35.4) [26]. ORR, 1- and 2-year
PFS and OS rates were similar between PD-L1 < 1%
and > 1% subsets (Table 2, complementary diagnos-
tic PD-L1 assay, Dako 28–8) [26]. In a subsequent
single-arm phase 2 study of 265 cisplatin-pretreated
patients, ORR was achieved in 19.6% (95% CI 15.0
to 24.9) in the overall cohort (N = 265), 28.4% (95%
CI: 18.9 to 39.5) in the PD-L1 ≥ 5% cohort (N = 81),
23.8% (95% CI: 16.5 to 32.3%) in the PD-L1 ≥ 1%
cohort (N = 81), and 16.1% (95% CI: 10.5 to 23.1)
in the PD-L1 < 1% cohort (N = 143). In these earlier
phase studies, higher PD-L1 expression seemed to
enrich for responders, but a significant proportion of
patients still responded despite being PD-L1 nega-
tive.
Durvalumab
In the expansion cohort of a phase 1/2 open-
label study consisting of 61 mBC patients, most
(93.4%) of whom received one or more prior ther-
apies for metastatic disease, the ORR was 31%
(95% CI: 17.6 to 47.1) in 42 response-evaluable
patients, 46.4% (95% CI: 27.5 to 66.1) in the PD-
L1 positive subgroup, and 0% (95% CI: 0 to 23.2)
in the PD-L1 negative subgroup (Table 1, comple-
mentary diagnostic PD-L1 assay SP263). Twelve of
13 responders have ongoing response (range: 4.1
to 49.3 weeks, median not reached) [6]. Updated
results from the same phase 1/2 open-label study,
consisting of 191 platinum-pretreated or platinum-
ineligible mBC patients demonstrated an ORR of
17.8% (95% CI: 12.7 to 24) in the overall cohort,
ORR of 27.6% (95% CI: 19 to 37.5) in the PD-L1
positive (n = 27, PD-L1 ≥ 25% TC or IC), and ORR
of 5.15 (95% CI: 1.4 to 12.5) in the PD-L1 low or
negative cohort (PD-L1 < 25% in both TC and IC)
[27]. In a single phase 1/2 study with a relatively
large expansion cohort, PD-L1 expression seems a
promising predictor of response, with the PD-L1 low
or negative cohort having low response rates. Longer
term follow-up and larger confirmatory studies need
to look at the value of this PD-L1 assay for PFS
and OS.
Avelumab
A phase 1b cohort of 44 treatment-refractory
mBC patients reported an independently assessed
ORR 18.2% (95% CI: 8.2 to 32.7, 5 complete
response and 3 partial responses). Seven of 8 respond-
ing patients had PD-L1 positive (PD-L1 TC ≥ 5%)
tumors (Table 1, complementary diagnostic PD-L1
assay 73–10) [7]. A pooled analysis combining two
phase 1 study cohorts (n = 249) comprising platinum-
pretreated patients and platinum-ineligible patients
reported an ORR 24% in the PD-L1 positive subgroup
and an ORR 13% in the PD-L1 negative subgroup
[28]. With this relatively small mixed population of
platinum-pretreated and platinum-ineligible patients,
determining the value of PD-L1 score conclusively is
challenging.
In conclusion, PD-1 and PD-L1 ICIs have become
commonplace in the treatment of many solid tumor
types including bladder cancer. Clearly, only a subset
of mBC patients benefit from these agents signif-
icantly. The use of PD-L1 expression to predict
response is limited by the heterogeneity of PD-L1
expression over time and geography, but also that
there are different diagnostic platforms and criteria
for scoring PD-L1 expression (Table 1). Examining
the present literature, PD-L1 testing seems to have the
greatest discriminatory ability of responders and non-
responders to durvalumab. However, a larger phase 3
study for durvalumab has yet to confirm these trends.
CD8+ T CELL INFILTRATION
Response to immunotherapy is dependent on T
cells invading the tumor and inducing an effective
immune reaction. Therefore, studies have focused on
tumor infiltrating lymphocytes, such as CD8+ T cells,
as a biomarker of response to therapy. In a study of
18 patients treated with pembrolizumab, durvalumab
or atezolizumab, CD8+ T cell infiltration assessed by
IHC significantly correlated with cancer-specific sur-
vival (CSS) (p = 0.013) [29]. Of the 212 patients from
a phase 2 trial of nivolumab in mBC (CheckMate-
275), 106 patient samples were analyzed for CD8+
T cells in the tumor by IHC, and which showed that
high CD8 expression is associated with longer PFS
(p = 0.0003) and OS (p = 0.01) [30].
The ratios of other immune cell subsets relative to
CD8+ T cells have also been used to better understand
the immune response in the tumor microenviron-
ment [31]. Inflammation is an important marker of
immunotherapy treatment outcome in cancer. Neu-
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trophils have been associated with poor prognosis
since they can suppress cytotoxic T cell activity [32,
33]. In a phase 1/2 open-label expansion study of dur-
valumab in patients with locally-advanced and mBC,
lower neutrophil-to-lymphocyte ratio at baseline was
associated with increased tumor response rate as well
as prolonged survival [34].
CD8+ T cell infiltration into the tumor microen-
vironment is necessary, but not sufficient to predict
anti-cancer response. This suggests that response to
immunotherapy is not dependent on only one cell
subset, but more so on the proportion of the different
immune cell subsets, specifically a balance between
the anti-tumor, such as CD8+ T cells, amongst the
other cells in the tumor microenvironment.
Interferon-γ (IFNγ) signature
IFN is a requisite mediator of inflammation, with
a critical role in the recruitment of T cells and addi-
tional cellular mediators of the immune response
[35]. From a phase 2 trial of nivolumab in metastatic
UC (CheckMate-275), a 25-gene IFN and a 12-gene
chemokine expression profile was generated from
tumor tissue samples of 177 patients [36]. Based
on the 25-gene IFN signature, a high IFN sig-
nature was associated with response to nivolumab
(p = 0.0003). The authors also noted that the 12-gene
chemokine signature was highly enriched in tumors
from nivolumab responders, though the data was not
shown [35]. Overall, individuals who responded to
nivolumab were enriched for anti-tumor-associated
immune biomarkers such as CXCL9, CXCL10, and
CD8, which were part of the multi-gene signature.
CXCL9 and CXCL10 are ligands for the CXCR3
and have been shown to be mediators of CD8+ T
cell response [37–39].
In a retrospective study of patients treated with dur-
valumab, RNA sequencing of 97 non-small cell lung
cancer (NSCLC) patient tumors was undertaken as
part of a discovery set, which identified a four-gene
IFN signature [40]. The four-gene panel consisted of
IFN, CD274, LAG3 and CXCL9. The signature was
validated in 62 locally-advanced or mBC patients,
which showed a 3.5-fold higher ORR in patients with
the IFN signature compared with those who were
absent of the biomarker. Utilizing the same four-gene
IFN signature in another study, patients treated with
durvalumab within the top third of IFN signature
tumor expression were scored as positive [41]. These
patients had increased ORR (45% in IFN signature
positive cohort vs 16% in IFN signature negative), as
well as improved PFS (p = 0.005) and OS (p = 0.016)
compared to the IFN signature negative cohort [41].
As part of the KEYNOTE-012 study, a phase
1b study of pembrolizumab in multiple solid tumor
types, RNA sequencing was undertaken in an initial
discovery set of 19 melanoma patient tumor samples
followed by validation in 9 other solid tumor types
comprising 220 patients, of which 25 were bladder
cancer patient samples [42]. From this, a 10-gene
IFN signature and an expanded 28-gene immune
signature was derived. This study did not use these
gene signatures to determine if there was correlation
with clinical benefit in bladder cancer, since it was
used as part of the discovery dataset. The IFN and
immune signatures were used in the head and neck
squamous cell carcinoma (HNSCC) (n = 43) and gas-
tric cancer cohort (n = 33), with results showing that
a higher IFN signature score was correlated with
increased PFS (p < 0.001 and p = 0.032, respectively),
compared to those with a low IFN signature score.
While this study did not perform validation stud-
ies with bladder cancer data, results were confirmed
in two other solid tumor types. IFN signature is a
promising predictive molecular biomarker that may
complement other biomarkers. Overall, studies were
in heterogeneous populations, used different IFN-
associated genes measured by different techniques,
and findings have not been validated in independent
prospective studies.
Tumor Mutation Burden (TMB)
BC has one of the highest mutation rates after
lung carcinoma and melanoma [43]. TMB has been
strongly correlated with clinical benefit in other solid
tumors, and therefore is of great interest in BC
as well [44]. Whole exome sequencing was per-
formed on 250 patient samples from the IMvigor210
study; TMB and tumor neoantigen burden correlated
with response to atezolizumab (p = 6.9 x 10–7 and
p = 2.7×10–9, respectively) [45]. TMB was also pos-
itively associated with OS (p = 2.0 x 10–5) [45]. The
pathways most significantly associated with TMB
included cell cycle, DNA replication, and DNA dam-
age response (DDR) [45]. Tumors with at least one
mutation in DDR or cell cycle regulator genes had a
significantly higher TMB and higher response rates
to treatment (p = 0.0117) [45].
In contrast, another analysis also using data from
the IMvigor210 study, but looking at a smaller group
of just 29 patients saw no correlations with respect
to TMB, or expressed or predicted neoantigen load
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with durable clinical benefit [46]. The differences
between these two studies highlights the variabil-
ity amongst samples within a given trial, and the
difference in interpretations given a specific sam-
ple size. The authors of the 29-patient study went
on to pursue an alternate analysis of their patient
data to examine time-varying association between
mutation load and PFS, to determine if mutation
load had a differential association with three months
post-treatment versus more than three months post-
treatment [46]. This alternate analysis found evidence
of time-varying effects of somatic mutation load on
PFS (p = 0.044) [46]. In comparing TMB within the
first 3 months post-treatment versus more than 3
months post-treatment, there was a stronger associa-
tion of TMB with PFS at more than 3 months after
treatment, compared to that in the first 3 months [46].
This suggests that the association between mutation
load as a predictor of response is better over time.
In a phase 2 study looking at atezolizumab in first-
line treatment in 119 cisplatin-ineligible patients with
locally-advanced and mBC, TMB was found to be
higher in responders than non-responders, and was
consistent across TCGA subtypes and PD-L1 expres-
sion groups [12]. Higher TMB was associated with
better OS. The level of TMB had a direct relation-
ship with prolonged survival, where patients within
the top 25% of mutation load had longer survival
than those in the lower 75% [12]. In another study of
atezolizumab, looking at 310 patients with locally-
advanced and metastatic urothelial carcinoma who
had progressed after platinum-based chemotherapy,
a correlation between higher TMB and response to
atezolizumab was also observed [11].
The impact of TMB on nivolumab efficacy in
second-line BC patients was examined in CheckMate
275, a phase 2 study in 139 patients with analyzable
samples [47]. High TMB was associated with higher
ORR [TMB high, medium, low (31.9%, 17.4%,
10.9%), p = 0.002] and PFS [TMB high, medium, low
(3.02, 1.87, 1.91 months), p = 0.005], but not a signif-
icantly different OS [TMB high, medium, low (11.63,
9.66, 5.72 months), p = 0.067]. TMB was defined
in this study as the total number of somatic mis-
sense mutations per tumor, and was evaluated as a
continuous variable as high, middle/medium or low
tertiles [47]. Lastly, whole exome sequencing of 14
bladder cancer patients treated with pembrolizumab,
atezolizumab, or durvalumab examined the number
of nonsynonymous mutations [29]. The study showed
that a high TMB and neoantigen burden correlated
with CSS (p = 0.034 and p = 0.047, respectively). In
this study, high was defined as greater than or equal
to the median value.
Although pembrolizumab has been approved to
treat all unresectable or metastatic solid tumors that
are microsatellite instability-high (MSI-H) or mis-
match repair deficient (dMMR), the occurrence of
MSI-H or dMMR is rare. The presence of mismatch
repair deficiency may lead to a higher mutation load
or TMB. One study performed massively-parallel
sequencing and interrogation on 447 tumors from 424
urothelial cancers of different stages, and found only
13 out of 424 (3%) tumors were MSI-H [48]. Patients
with MSI-H tumors (n = 13) had a median mutation
count of 52 (36.5–73.5) versus 8 (5–13) in non-
dMMR patients (n = 410) (p < 0.01). All five of the
13 MSI-H patients that received immune checkpoint
blockade (drug not specified) for metastatic disease
achieved near complete or complete responses. All
13 dMMR patients were still alive compared to 125
out of 410 non-dMMR patients at 27 months of
follow-up (p = 0.014) [48]. Based on these data, high
TMB may be a good discriminator of responders and
non-responders, but questions remain regarding the
optimal definition of high TMB, the panel of interro-
gated genes, and the accuracy of the techniques and
technology. Despite being rare, MSI-H / dMMR sta-
tus should be a strong predictor of clinical benefit
from PD-1 blockade in those who have it.
T cell receptor (TCR) clonality
T cell receptors (TCR) recognize antigens pre-
sented by the major histocompatibility complex
(MHC). The immune system is marked by TCR
diversity, which is indicative of how many differ-
ent antigens the T cell can recognize and respond
to. The clonality of the TCR, indicated by a higher
proportion of one subset, suggests a clonal expan-
sion of T cells in response to a specific stimulus.
TCR clonality can be detected by sequencing of
the CDR3 region of the T cell and high prevalence
of a sequence is indicative of T cell expansion in
response to a stimulus, for instance a tumor antigen.
Higher TCR clonality has been shown to be associ-
ated with response to immune checkpoint blockade
in melanoma, breast and prostate cancer [49–52].
In an analysis of 15 patients with urothelial car-
cinoma treated with pembrolizumab, durvalumab
or atezolizumab, the TCR of tumor-infiltrating T
cells were sequenced from fresh-frozen, paraffin-
embedded (FFPE) tissue blocks, which led to the
identification of highly diverse population (1557 to
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41,435) of TCR clonotypes [29]. Limited by a small
sample size, no conclusion could be made in terms of
correlation with longer CSS (R = –0.522, p = 0.055).
In a retrospective cohort study of 29 metastatic
urothelial cancer patients treated with atezolizumab,
the TCR clonality of peripheral T cells were analyzed
[46]. Pretreatment peripheral blood TCR clonality
below the median was associated with improved PFS
(p = 0.048) and OS (p = 0.01). A high pretreatment
peripheral blood TCR clonality was strongly associ-
ated with poor clinical outcome. However, following
atezolizumab treatment, expansion of TCR clones
in the peripheral blood was associated with durable
clinical response (p = 0.01). This suggests that low
clonality prior to treatment, followed by increased
clonality post-treatment is beneficial. These studies,
though small in size, suggest that analysis of TCR
clonality in blood as well as in the tumor microen-
vironment (TME) would provide clinical insight to
response, and that expansion of TCR clones following
treatment is associated with clinical benefit.
Epithelial-Mesenchymal Transition (EMT)
Equally important as discovering molecular mark-
ers to predict clinical benefit is the need to
discover markers to predict the potential to do
harm. Epithelial-mesenchymal transition (EMT) is
the process in which epithelial cells, which normally
interacts with the basement membrane via its basal
surface, undergo multiple changes, enabling cells to
assume a mesenchymal phenotype, which enhances
migratory capacity. In this context, EMT has been
associated with more aggressive tumor types [53,
54]. One study suggests that EMT presence, deter-
mined based on a 200-gene signature expression
from The Molecular Signatures Database (MSigDB),
may be a potential mechanism of tumor immune
evasion during nivolumab treatment of urothelial can-
cers with high CD8+ T cell infiltration, which are
normally immunologically responsive to tumor cells
[30]. EMT, as a marker on its own, at high levels
is associated with worse ORR (EMT high 13.2% vs
EMT low 23.6%), PFS (EMT high 1.91 [1.81–2.46]
vs EMT low 2.10 [1.87–3.65]) and OS (EMT high
6.57 [4.96-NR] vs EMT low (8.74 [6.05-NR) [30].
EMT has historically been associated with subopti-
mal response to chemotherapy, progression of disease
and development of metastases [53, 54]. This is a
longstanding problem that is complicated and poorly
understood. Key questions will include whether the
mesenchymal state can be reverted to an epithelial
state to re-establish an immune-sensitive microenvi-
ronment, or otherwise develop strategies to address
cancer with mesenchymal properties directly.
Transforming growth factor β (TGFβ)
Mariathason et al, using samples from the
IMvigor210 trial which looked at a large cohort of
mBC patients, found that a lack of response to ate-
zolizumab was associated with transforming growth
factor  (TGF) signaling in fibroblasts [45]. TGF
is particularly associated with a lack of response in
patients whose tumors are classified by an “excluded
tumor-immune” phenotype, which is defined as the
localization of the immune cells, particularly the
CD8+ T cells, in the fibroblast and peritumoral
stroma, rather than in the tumor parenchyma. Com-
bining anti-TGF and anti-PD-L1 may have the
potential to reverse checkpoint resistance, based on
early data in murine tumor models [45]. In conclu-
sion, further investigation on the role of TGF will
be paramount to inform future strategies to address
intrinsic resistance and perhaps acquired resistance
to PD-1/PD-L1 inhibitors.
DISCUSSION
Over the last few years, results from multiple
studies have led to accelerated FDA approval of
multiple ICIs. Results from these clinical trials led
to a shift in mBC treatment paradigms with the
inclusion of ICIs in international guidelines that
now recommend atezolizumab and pembrolizumab
in the first-line setting for cisplatin-ineligible patients
with high PD-L1 score or regardless of PD-
L1 status in platinum-ineligible patients [55, 56].
Moreover, in the second-line setting, atezolizumab,
pembrolizumab and nivolumab are recommended
for mBC patients with progression during or after
platinum-based combination chemotherapy [55, 56].
Avelumab and durvalumab are recommended for the
treatment of locally advanced or metastatic urothelial
carcinoma whose disease progressed during or fol-
lowing platinum-containing chemotherapy or within
12 months of neoadjuvant or adjuvant platinum-
containing chemotherapy [57, 58].
Along with these encouraging developments,
many questions arise since the cost of ICI treatment
is significant and the toxicity is not negligible. These
questions are driven by the observed heterogeneity
of response to ICIs, the risk of pseudoprogression
(initial tumor burden increase followed by tumor
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shrinkage) which introduces further challenges to
the decision-making process in clinical practice, as
well as accelerated disease progression in a small
subset of patients (hyperprogression) [23, 59–62].
One important change is the FDA requirement for
cisplatin-ineligible patients to have a sufficiently
high PD-L1 score before the start of PD-1/PD-L1
inhibitor monotherapy since decreased survival in
patients with low PD-L1 expression treated with
pembrolizumab or atezolizumab in the first-line set-
ting was shown in KEYNOTE-361 and IMvigor-130
[19–21]. On the other hand, patients who are not
eligible for any platinum-based chemotherapy may
receive pembrolizumab or atezolizumab regardless
of PD-L1 score.
The immune response is a complex system that
involves both the tumor and its TME including the
complete spectrum of immune cells (e.g. cytotoxic
T cells, suppressive regulatory T cells, natural killer
cells, macrophages). Most studies on ICIs investi-
gated the role of PD-L1 protein expression on either
the tumor alone and/or expression on immune cells
depending on which PD-L1 antibody was used. Over-
all, PD-L1 expression correlates with higher response
rates, but also a large portion of the patients with
a high PD-L1 expression do not respond, whereas
some considered PD-L1 low or negative can still
respond to treatment. While progress has been made
to identify novel predictive biomarkers of response to
ICIs, such as TMB, TCR clonality, and IFN signa-
ture, most studies should be considered preliminary
due to small cohort size and the lack of indepen-
dent validation (Fig. 2). The complexity of the tumor
microenvironment, and the lack of robust models to
study these interactions currently hamper progress.
Although the discrepant findings between PD-1/PD-
L1 ICI studies could be caused by the use of different
antibody clones, staining platforms, and scoring sys-
tems (Table 1), a recent study indicated a pairwise
agreement of 80–90% between the most frequently
used IHC PD-L1 antibodies (22C3, 28–8, SP12 and
SP263) [63].
Combining ICI therapies that enhance anti-tumor
immunity has been an area of great interest. This is
reflected by the number of clinical trials exploring
combinations aimed at enhancing response to this
relatively new class of anti-cancer drugs, which
has soared from a single trial in 2009 to over 1100
in 2017 [64]. Some examples in bladder cancer
of active, recruiting trials include a single-arm
phase 2 trial looking at neoadjuvant pembrolizumab
in combination with gemcitabine and cisplatin
Fig. 2. Ranking of the predictive value of molecular biomark-
ers for response to PD-1/PD-L1 immune checkpoint blockade.
Biomarkers closer to the center are more predictive of response.
High predictive value: tumor mutation burden. Moderate predictive
value: TGF signature, CD8 T cell infiltration, interferon-. Low
predictive value: microsatellite instability, PD-1/PD-L1 expres-
sion level, TCR clonality. Predictive level was assessed based on
the amount of published data and the quality of these studies, as
evaluated and determined in consensus by all authors.
(NCT02690558). The BLASST-1 (Bladder Cancer
Signal Seeking Trial) phase 2 study is recruiting
MIBC patients with localized disease to explore a
combination of nivolumab with gemcitabine and cis-
platin in the neoadjuvant setting before a cystectomy
(NCT03294304). Other phase 2 trials include com-
bination studies of avelumab with chemoradiation
in MIBC patients (NCT03617913) and nivolumab
with radiotherapy in cisplatin-ineligible patients
(NCT03421652).
In conclusion, we still have not uncovered the true
mechanisms leading to effective tumor clearance by
ICIs, and no single available biomarker can strat-
ify patient response. As the tumor-related immune
response is a multistep process that involves multiple
aspects of the immune system, a nomogram combin-
ing biomarkers from different steps of the response
could provide the solution to this complex interaction.
Additionally, more studies are needed to elucidate the
molecular genetic underpinnings of the fundamental
biological response to ICI treatment. Recently, appli-
cation of functional genomic approaches has yielded
novel insights to such mechanism and has the poten-
tial for determining effective drug combinations with
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ICIs, as well as predictive biomarkers for the use of
such combinations [65].
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APPENDIX 1
Database: Embase Classic+Embase <1947 to 2019
January 07>, Ovid MEDLINE(R) ALL <1946 to Jan-
uary 07, 2019>, EBM Reviews - Cochrane Central
Register of Controlled Trials <December 2018>
Search Strategy:
1 Urinary Bladder Neoplasms/sc [Secondary]
(591)
2 Carcinoma, Transitional Cell/sc [Secondary]
(1397)
3 Urinary Bladder Neoplasms/ or Carcinoma,
Transitional Cell/ (76902)
4 ((bladder or urothelial) adj3 (cancer* or
neoplasm* or tumor* or tumour* or carci-
noma*)).tw. (133033)
5 ((bladder or urothelial) and (cancer* or
neoplasm* or tumor* or tumour* or carci-
noma*)).kf. (9487)
6 3 or 4 or 5 (158803)
7 exp Neoplasm Metastasis/ (797411)
8 metast*.tw,kw. (1167908)
9 7 or 8 (1390214)
10 6 and 9 (28881)
11 1 or 2 or 10 (29336)
12 atezolizumab.mp. (3325)
13 durvalumab.mp. (2245)
14 avelumab.mp. (1399)
15 BMS-936559.mp. (392)
16 nivolumab.mp. (13963)
17 pembrolizumab.mp. (11027)
18 (checkpoint block* or check point block*
or checkpoint inhibitor* or check point
inhibitor*).tw,kw. (20623)
19 PD-L1.tw,kw. (22737)
20 PD-1.tw,kw. (29759)
21 (immune checkpoint or immune check
point).tw,kw. (18138)
22 (CTLA-4 or CTLA4).tw,kw. (22889)
23 CTLA-4 Antigen/ai [Antagonists & Inhibitors]
(691)
24 Programmed Cell Death 1 Receptor/ai [Antago-
nists & Inhibitors] (1372)
25 or/12-24 (75074)
26 11 and 25 (1297)
27 exp animals/ not humans/ (16935118)
28 26 not 27 (902)
29 28 use medall (316) Medline
30 exp bladder cancer/ (116923)
31 transitional cell carcinoma/ (43663)
32 30 or 31 (136611)
33 exp metastasis/ (797411)
34 32 and 33 (16760)
35 (metast* adj5 ((bladder or urothelial) adj3 (can-
cer* or neoplasm* or tumor* or tumour* or
carcinoma*))).tw. (8104)
36 bladder metastasis/ (1197)
37 34 or 35 or 36 (21293)
38 antineoplastic monoclonal antibody/ or ate-
zolizumab/ or avelumab/ or bms 936559/ or
durvalumab/ or nivolumab/ or pembrolizumab/
(15335)
39 (atezolizumab or avelumab or bms 936559
or durvalumab or nivolumab or pem-
brolizumab).tw. (14518)
40 (checkpoint block* or check point block*
or checkpoint inhibitor* or check point
inhibitor*).tw. (19604)
41 ((ctla-4 or pd-1 or pd-l1) adj4 (antibod* or
inhibitor*)).tw. (15052)
42 *programmed death 1 ligand 1/ (5291)
43 or/38-42 (43827)
44 37 and 43 (1115)
45 (exp animal/ or nonhuman/ or animal experi-
ment/) not exp human/ (11408775)
46 44 not 45 (1095)
47 46 use emczd (799) Embase
48 Urinary Bladder Neoplasms/sc [Secondary]
(591)
49 Carcinoma, Transitional Cell/sc [Secondary]
(1397)
50 Urinary Bladder Neoplasms/ or Carcinoma,
Transitional Cell/ (76902)
51 ((bladder or urothelial) adj3 (cancer* or
neoplasm* or tumor* or tumour* or carci-
noma*)).tw. (133033)
52 (bladder cancer or bladder neoplasms* or blad-
der tumor* or bladder tumour*).kw. (21939)
53 50 or 51 or 52 (159545)
54 exp Neoplasm Metastasis/ (797411)
55 metast*.tw,kw. (1167908)
56 54 or 55 (1390214)
57 53 and 56 (29009)
58 48 or 49 or 57 (29464)
59 atezolizumab.mp. (3325)
60 durvalumab.mp. (2245)
61 avelumab.mp. (1399)
62 BMS-936559.mp. (392)
63 nivolumab.mp. (13963)
64 pembrolizumab.mp. (11027)
65 (checkpoint block* or check point block*
or checkpoint inhibitor* or check point
inhibitor*).tw,kw. (20623)
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66 PD-L1.tw,kw. (22737)
67 PD-1.tw,kw. (29759)
68 (immune checkpoint or immune check
point).tw,kw. (18138)
69 (CTLA-4 or CTLA4).tw,kw. (22889)
70 CTLA-4 Antigen/ai [Antagonists & Inhibitors]
(691)
71 Programmed Cell Death 1 Receptor/ai [Antago-
nists & Inhibitors] (1372)
72 or/59-71 (75074)
73 58 and 72 (1302)
74 73 use cctr (122)
75 29 or 47 or 74 (1237) Cochrane
76 remove duplicates from 75 (967)
77 76 use medall (313) Medline
78 76 use emczd (566) Embase
79 76 use cctr (88) Cochrane
